A5103117207- Systemic Lupus Erythematosus Research
- Atherosclerosis and Cardiovascular Diseases
- Monoclonal and Polyclonal Antibodies Research
- Multiple Myeloma Research and Treatments
- Renal Diseases and Glomerulopathies
- Peripheral Neuropathies and Disorders
- Systemic Sclerosis and Related Diseases
- Protein Degradation and Inhibitors
- Liver Disease Diagnosis and Treatment
- Rheumatoid Arthritis Research and Therapies
- Vasculitis and related conditions
- T-cell and B-cell Immunology
- Peptidase Inhibition and Analysis
- Liver Diseases and Immunity
- Adrenal Hormones and Disorders
- Psoriasis: Treatment and Pathogenesis
- Multiple Sclerosis Research Studies
- Prostate Cancer Treatment and Research
- Cancer Treatment and Pharmacology
- Cytokine Signaling Pathways and Interactions
- Prostate Cancer Diagnosis and Treatment
- Lipid metabolism and disorders
- Spondyloarthritis Studies and Treatments
- Health Systems, Economic Evaluations, Quality of Life
- Burn Injury Management and Outcomes
University of Toronto
2015-2024
University Health Network
2015-2024
Toronto Western Hospital
2013-2024
Suzhou Municipal Hospital
2019-2024
Nanjing Medical University
2019-2024
Canadian Apheresis Group
2024
Krembil Research Institute
2016-2024
Shenzhen Institutes of Advanced Technology
2024
Medical Decision Modeling (United States)
2024
AstraZeneca (Canada)
2024
Abstract Objective The antimalarial medication hydroxychloroquine has been proposed as a thromboprotective agent in systemic lupus erythematosus (SLE), but studies thus far have limited by the possibility of confounding indication. This study was conducted to assess whether exposure drugs is associated with decrease thrombovascular events (TEs) patients SLE. Methods designed nested case–control embedded an inception cohort SLE, which allowed adjustments for possible calendar year, duration...
Abstract Due to evolving treatment standards for newly diagnosed multiple myeloma, many patients will be triple-class exposed after initial relapses and have poor survival. Novel therapies combinations are therefore required improve outcomes. B cell maturation antigen (BCMA)-targeted biologics emerged as an important new area of therapeutics relapsed myeloma. The two-part ALGONQUIN trial evaluated various doses schedules the anti-BCMA antibody–drug conjugate belantamab mafodotin plus...
Objective. To assess whether hydroxychloroquine (HCQ) prevents early damage in patients with systemic lupus erythematosus (SLE). Methods. We updated an existing systematic review of literature on clinical effects HCQ SLE. conducted a nested case-control study embedded inception cohort Systemic Lupus International Collaborating Clinics Damage Index (SDI) at 3 years was considered as our primary outcome. Patients SDI > 0 were cases and = controls. Cases controls first compared by univariate...
<h3>Background</h3> Survival in systemic lupus erythematosus (SLE) has improved substantially the last 50 years. The aim of present study was to assess evolution all-cause, cause-specific and age-specific standardised mortality ratios (SMRs) patients with Ontario, Canada. <h3>Patients methods</h3> Between 1971 2013, 1732 were followed Toronto Lupus Clinic. Causes death retrieved from certificates, autopsy reports, hospital records or family physicians. They categorised as atherosclerotic,...
Objective To define and identify a group of systemic lupus erythematosus patients with low disease activity (LDA) to examine whether LDA is similar in remission different from high (HDA) short‐term outcomes. Methods The was defined as Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI‐2K) <3, including only 1 clinical manifestation rash, alopecia, mucosal ulcers, pleurisy, pericarditis, fever, thrombocytopenia, or leukopenia. could be taking antimalarials. Remission no...
Disease activity in systemic lupus erythematosus follows three different courses: long quiescent, relapsing remitting and persistently active. However, the patterns of disease course since diagnosis are not known. This study aimed to assess prevalence characteristics such over 10 years.The inception cohort Toronto Lupus Clinic (≥10 year follow up, between visit interval ≤18 months) was investigated. Prolonged remission defined as a clinical Systemic Erythematosus Activity Index 2000 = 0...
Objective. The traditional Framingham Risk Factor Score (FRS) underestimates the risk for coronary artery disease (CAD) in patients with systemic lupus erythematosus (SLE). We aimed to determine whether an adjustment FRS would more accurately reflect higher prevalence of CAD among SLE. Methods. Patients SLE without a previous history or diabetes followed regularly at University Toronto Lupus Clinic were included. A modified (mFRS) was calculated by multiplying items 1.5, 2, 3, 4. In first...
To describe the frequency of myocardial infarction (MI) prior to diagnosis systemic lupus erythematosus (SLE) and within first 2 years follow-up.The international collaborating clinics (SLICC) atherosclerosis inception cohort enters patients 15 months SLE diagnosis. MIs were reported attributed on a specialised vascular event form. confirmed by one or more following: abnormal ECG, typical atypical symptoms with ECG abnormalities elevated enzymes (≥2 times upper limit normal), stress test,...
Objectives Patients with systemic lupus erythematosus (SLE) are usually treated glucocorticosteroids even during periods of clinically quiescent disease. A recent study showed that abrupt glucocorticoid withdrawal was associated an increased likelihood flare in the next 12 months. The aim present to assess clinical rates and damage accrual patients who tapered gradually. Methods from Toronto Lupus Clinic 2 consecutive years disease were retrieved database. Individuals maintained a low...
Abstract Objective To determine the prevalence, accrual over time, and risk factors of work disability in patients with systemic lupus erythematosus (SLE). Methods We studied 432 from an inception cohort. Work was measured a single self‐report question. Data were prospectively collected included sociodemographic information, clinical features including activity (Systemic Lupus Erythematosus Disease Activity Index 2000 update [SLEDAI‐2K]), damage International Collaborating Clinics/American...
There is a need for cognitive function screening test that can be administered to patients with systemic lupus erythematosus (SLE) in clinic. The objectives of this study were determine (1) prevalence impairment (CI) SLE by the Montreal Cognitive Assessment (MoCA), Mini Mental State Examination (MMSE), relation Hopkins Verbal Learning Test-Revised (HVLT-R), and Perceived Deficits Questionnaire 5-Item (PDQ-5); (2) associated factors CI.Consecutive followed at single center recruited. HVLT-R,...
Objective. We previously reported the effect of certain factors on cardiovascular disease (CVD) in 250 women with systemic lupus erythematosus (SLE) followed for 8 years. The aim this study was to delineate their evolution after 15 years followup. Methods. There were 210 SLE and 138 age-matched healthy available analysis Cardiovascular events (CVE) included angina pectoris, myocardial infarction (fatal nonfatal), transient ischemic attack, stroke nonfatal). Analysis performed SAS 9.3...
The objective of this study was to determine the clinical significance renal vascular lesions in lupus nephritis.Renal defined as thrombotic microangiopathy, vasculopathy, uncomplicated immune deposits, and arterial sclerosis were evaluated relation morbidity overall mortality.Biopsies from 161 patients revealed microangiopathy (13), vasculopathy (5), (93). No found 24.8% patients. At time biopsy, or older (arterial sclerosis=37.9±13.0 vasculopathy=44.4±8.9 versus controls=33.1±8.9 years,...
Background Systemic lupus erythematosus (SLE) patients are often treated with glucocorticoids, which place them at risk of bone loss. Objectives The objectives this article to determine: (1) the prevalence low mineral density (BMD) and factors associated BMD (2) symptomatic fragility fractures in inception Toronto Lupus Cohort (TLC). Methods Prospectively collected data from TLC (1996-2015) patients' first were analyzed. For pre-menopausal women/males <50 years, 'below expected range for...
Objective. Mycophenolate mofetil (MMF), along with corticosteroids, is considered as the standard of care in lupus nephritis (LN); however, little known regarding its efficacy extrarenal manifestations systemic erythematosus (SLE). We aimed to determine effectiveness nonrenal SLE. Methods. One hundred seventy-seven patients SLE were enrolled; 105 for whom MMF was introduced active LN (mean age 35.6 ± 10.7 yrs, mean disease duration 8.9 7.8 yrs) and 72 38.6 11.7 9.2 yrs). The main indication...
Background: MedsCheck Annual (MCA) is an Ontario government-funded medication review service for individuals taking 3 or more prescription medications chronic conditions. Methods: This cohort study analyzed linked administrative claims data from April 1, 2007, to March 31, 2013. Trends in MCA and recipient characteristics were examined. Results: A total of 1,498,440 Ontarians (55% seniors, 55% female) received MCA. One-third (36%) had 2 MCAs within 6 years. Service provision increased over...
Objective. To examine the role of disease activity on organ damage over 5 years in patients with active systemic lupus erythematosus (SLE) despite standard care. Methods. This analysis University Toronto Lupus Clinic cohort assessed [measured by Systemic International Collaborating Clinics/American College Rheumatology Damage Index (SDI)] SLE [SLE Disease Activity 2000 (SLEDAI-2K) ≥ 6], using Cox proportional time-independent hazard models. Subgroup analyses were conducted SLEDAI-2K 6 or 7,...
Objectives This study aimed to evaluate the prevalence and incidence of herpes zoster (HZ) events describe its associated factors in a patients with SLE. Methods 491 consecutive SLE participants were screened for HZ using patient-reported questionnaire capture outcomes on pain other characteristics events. Sociodemographic, clinical laboratory measures also analysed, time-dependent Cox regression survival analyses performed investigate Results Prevalence was 30.5%, 14.3 cases per 1000...